南洋行家论股
柔佛医药保健 拓东南亚版图
目标价：1.18令吉
最新进展:
柔佛医药保健（KPJ，5878，主板贸服股）以1亿1992万226令吉，脱售独资子公司Lablink（马）私人有限公司股权给Quadria资本。
同时，Quadria资本也会认购Lablink新股。
最终，Quadria资本会持有Lablink的 49%股权，剩余51%仍是柔佛医药保健所有。
行家建议:
我们正面看待该交易，因为与扩展病理与诊断业务计划一致。
上述合作让柔佛医药保健扩大版图至东南亚新增长市场，并拥有具经验的伙伴，同时转移集团的资本开销负担。
截至去年第3季，公司现金盈余为3亿1820万令吉，净负债率达0.76倍。
假设该认购与购股协议所得将用于抵消借贷，净负债率料降低至0.69倍。
我们维持盈利预测、“买入”评级与1.18令吉目标价。
青睐纯大马医院主题的柔佛医药保健，该公司的利基是区域医院网络，将病人送入旗下城市专科医院。
http://www.enanyang.my/news/20180125/柔佛医药保健br-拓东南亚版图/
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
2024-10-04
KPJ2024-10-04
KPJ2024-10-04
KPJ2024-10-03
KPJ2024-10-03
KPJ2024-10-03
KPJ2024-10-02
KPJ2024-10-02
KPJ2024-10-02
KPJ2024-10-01
KPJ2024-10-01
KPJ2024-10-01
KPJ2024-09-30
KPJ2024-09-30
KPJ2024-09-30
KPJ2024-09-27
KPJ2024-09-27
KPJ2024-09-27
KPJ2024-09-26
KPJ2024-09-26
KPJ2024-09-26
KPJ2024-09-26
KPJ2024-09-26
KPJ2024-09-25
KPJ2024-09-25
KPJ2024-09-25
KPJ2024-09-24
KPJ2024-09-24
KPJ2024-09-24
KPJ
More articles on 南洋行家论股
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
Good Articles to Share
Singapore ends 181 years of horse racing to make way for homes
2
Good Articles to Share
3
Good Articles to Share
4
Good Articles to Share
5
Good Articles to Share
India's ruling party set to lose two state elections, exit polls show
6
Good Articles to Share
Dubai's Emirates Airlines bans pagers, walkie-talkies after Lebanon attacks
7
Good Articles to Share
Africa Rate Decisions: South Africa, Ghana Cut; Nigeria Hikes
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
